Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept

Hereditary Hemorrhagic Telangiectasia Clinical Trial

Official title:

Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01752049
• Other study ID #: BVMC 6207
• Secondary ID: 2U54NS065705-06
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: May 2013
• Est. completion date: August 30, 2019

Study information

• Verified date: August 2023
• Source: Unity Health Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hereditary hemorrhagic telangiectasia (HHT) is a hereditary vascular condition characterized by the development of abnormal connections between arteries and veins throughout the body, called vascular malformations. These abnormal blood vessels are referred to as arteriovenous malformations (AVM) if they are large and telangiectasias if they are small. Telangiectasias develop due to irregular growth of blood vessels.

Anti-angiogenic therapy, such as the drug Apo-Timop, curbs the growth of new blood vessels. Apo-Timop is included in a class of medications called beta-blockers. Anti-angiogenic therapies exert their beneficial effects in a number of ways: by disabling the agents that activate and promote cell growth, or by directly blocking the growing blood vessel cells.

The investigators think that anti-angiogenic therapy may lead to the shrinking of telangiectasia in people with HHT. The investigators hope that this study will provide us with proof of this concept and might lead to the development and study of anti-angiogenic therapies to help improve the lives of individuals with vascular malformations.

Description:

This is a small study of 5 patients from St. Michael's Hospital who have HHT and at least 5 typical telangiectasias.

Patients who anticipate a major surgery during this study or are pregnant, breast feeding or on other beta blocker medication may not enroll in this study.

This study lasts 12 weeks (84 days). During this time, subjects will apply a drop of either Apo-timop 0.5% or a placebo solution to 4 telangiectasias twice daily.

The active study medication is called Apo-Timop and is a clear liquid solution stored in a bottle. An eye dropper is used for application.

• Apo-timop will be applied to 3 telangiectasias and

• a placebo will be applied to one telangiectasia A placebo is an inactive substance, with no active medication in it, and it looks the same as the real medication. There is no potential harm of receiving the placebo. It is necessary to use a placebo to make sure that the effect of Apo-timop can be determined without any bias.

Subjects will receive four numbered bottles for every 28 day period as well as a photo which indicates which bottle is to be applied to which telangiectasia.

Neither the subject nor the research staff will know which telangiectasia will receive the placebo.

Apo-timop, is not part of the standard therapeutic regimen for HHT. It is a Health Canada approved medication which is applied as an eye drop, that has been shown to reduce pressure in the eye and is commonly used for glaucoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: August 30, 2019
• Est. primary completion date: August 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Definite clinical or genetic diagnosis of HHT

2. Known ENG or ALK1 mutation (personal or familial)

3. Age>=18 years

4. At least 5 typical (round/ovoid, not spider or linear) cutaneous telangiectasia (size range 2-5mm) on hands (not including lesions on over inter-phalangeal joints) or face

Exclusion Criteria:

1. Contraindication to systemic beta-blocker (severe asthma, severe COPD, sinus bradycardia, 2nd or 3rd degree AV block, overt heart failure, hypotension, allergy/intolerance/ hypersensitivity to timolol)

2. Current treatment with systemic beta-blocker

3. Current participation in other therapeutic trial for HHT

4. Current pregnancy or breastfeeding.

Related Conditions & MeSH terms

• Hereditary Hemorrhagic Telangiectasia
• Telangiectasia, Hereditary Hemorrhagic
• Telangiectasis

Intervention

Drug:
• Topical timolol maleate
Topical timolol maleate 0.5% drops Applied twice daily for 12 weeks (84 days) or until disappearance of lesions Study drops will be applied to 3 cutaneous telangiectasias per patient
• placebo saline drops
Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.

Locations

Country	Name	City	State
Canada	St. Michael's Hospital	Toronto	Ontario

Sponsors (7)

Lead Sponsor	Collaborator
Unity Health Toronto	National Institute of Neurological Disorders and Stroke (NINDS), Sunnybrook Health Sciences Centre, The Hospital for Sick Children, Toronto Metropolitan University, University of California, San Francisco, University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Lesion Area of Treated Telangiectasia.	Change in lesion area (compared with baseline measurement) of treated telangiectasia.	84 days
Secondary	Descriptive Changes in Histopathology in Baseline vs Treated Lesions		84 days
Secondary	Serum Angiogenic Markers		84 days
Secondary	Stability of Area of Untreated Telangiectasias Over the 84 Day Period		84 days
Secondary	Blood Flow Velocity and Volume Flow Rates		84 days